A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

Summary

Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.

Timeline

Start

2022-02-03

Primary completion

2022-12-15

Completion

2022-12-15

Outcome

Met primary endpoint

paper At week 16, the percentages of patients with a PASI 75 response were higher among those in the JNJ-77242113 groups PMID 38324484 ↗

paper than among those in the placebo group (9%), a finding that showed a significant dose-response relationship (P<0.001). PMID 38324484 ↗

Publications

• Strawn D, Krueger JG, Bissonnette R, Eyerich K, Ferris LK, Paller AS, Pinter A, Richards D, Chen EY, Paget K, Horowitz D, Parast R, Rusbuldt JJ, Sendecki J, Bhagat S, Tomsho LP, Chou CH, Polak ME, Keyes BE, Bozenhardt E, Xiong Y, Zhou W, DeKlotz C, Newbold P, Waterworth DM, Miller M, Ota T, Yang YW, Leung MW, Miller LS, Cuff CA, McRae B, Ruane D, Kannan AK. Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis. JCI Insight. 2025 Dec 22;10(24):e193563. doi: 10.1172/jci.insight.193563. eCollection 2025 Dec 22.
• Bissonnette R, Pinter A, Ferris LK, Gerdes S, Rich P, Vender R, Miller M, Shen YK, Kannan A, Li S, DeKlotz C, Papp K. An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis. N Engl J Med. 2024 Feb 8;390(6):510-521. doi: 10.1056/NEJMoa2308713.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Icotrokinra	Peptide	25 mg	Oral
Subject	Icotrokinra	Peptide	50 mg	Oral
Subject	Icotrokinra	Peptide	100 mg	Oral

Indications